TY - JOUR T1 - Comparison of health status in stable patients with bronchiectasis due to common variable immune deficiency (CVID), and idiopathic bronchiectasis JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p945 AU - Lorraine Ozerovitch AU - Samantha Prigmore AU - Winston Banya AU - Robert Wilson AU - Noel Snell AU - Peter Kelleher AU - Jillian Riley Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p945.abstract N2 - Background: Patients with CVID develop bronchiectasis (bx) due to damage caused by lung infections. Bx is associated with impaired health status (Wilson C et al Am J Respir Crit Care Med 1997; 156: 536-541). Improved treatment for CVID+bx has led to fewer infections but little is known about impact on health status.Methods: Patients undertook a Shuttle Walking Test (SWT) and completed the St George's Respiratory Questionnaire (SGRQ). Scores were compared with data from a previous study of idiopathic bx (Ozerovitch L et al Am J Respir Crit Care Med 2004; 169: A330).Results: 22 patients participated; 9 male (41%); mean age 45 (range 17-67); 20 (91%) on immunoglobulin (Ig) therapy. Patients with CVID+bx had better scores for all SGRQ domains, and better SWT, both of which were clinically relevant; SGRQ >4 point difference (Jones P, Eur Respir J 2002; 19: 398-404); SWT 60-115m (Pepin V et al, Thorax 2011;66:115-120), although neither attained statistical significance.View this table:There were no significant correlations between SWT and activity component or SGRQ Total Score (r= -0.45, p>0.05; r= -0.43, p>0.05) in the CVID with bx group.Conclusion: Patients with bx due to CVID have impaired health status and SWT; scores were generally better than for demographically similar historical controls with idiopathic bx, possibly as a result of specific therapy (Ig replacement) in the majority of these patients. ER -